About The ASCO Post
Rights and Permissions
In the Clinic
View By Issue
2018 ASCO Annual Meeting
23rd Congress of EHA
AACR Annual Meeting 2018
Methotrexate–Induced Kidney Injury
2013 American Society of Pediatric Hematology Oncology Annual Meeting
Today In Oncology
EHA 2018: Elotuzumab Plus Pomalidomide and Low-Dose Dexamethasone vs Pomalidomide/Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma
EHA 2018: Obinutuzumab or Rituximab Plus Chlorambucil in CLL
EHA 2018: Alvocidib in Patients With Relapsed or Refractory MCL-1–Dependent AML
Final Overall Survival Analysis of First-Line Crizotinib vs Chemotherapy in Advanced
EHA 2018: Tisagenlecleucel Demonstrates More Than 1-Year Durability of Response in Adults With Relapsed or Refractory DLBCL
Most Read Stories
ASCO Clinical Practice Guideline Focused Update: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer
PD-L1 Inhibitor Consolidation Therapy for NSCLC: New Standard of Care?
Surveillance Intensity Not Associated With Earlier Detection of Recurrence or Improved Survival in Patients With Colorectal Cancer
FDA Approves Pembrolizumab for Previously Treated Recurrent or Metastatic PD-L1–Expressing Cervical Cancer
Low-Fat Dietary Intervention and Overall Survival After Breast Cancer Diagnosis
© 2018 HSP News Service, L.L.C.
to learn more.